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ABSTRACT
Neonatal diabetes presents <6 months of life but delays 
in recognition result in presentation with life- threatening 
hyperglycaemia/diabetic ketoacidosis. Early identification 
and rapid genetic diagnosis is crucial and ensures correct 
treatment/management. Adding ‘glucose’ to newborn 
bloodspot screening (NBS) could aid prompt detection but 
requires evidence of parental acceptance.
Objectives Increase understanding of parental experience 
of presentation/recognition of neonatal diabetes and 
perceptions of glucose testing within NBS.
Setting UK families confirmed with a genetic diagnosis of 
neonatal diabetes, November 2014–2018, were invited to 
participate.
Participants In- depth qualitative interviews were 
conducted with 10 parents of 14 children. 8 had transient 
neonatal diabetes: KCNJ11 (n=5), ABCC8 (n=1), 6q24 
(n=2), 6 had permanent neonatal diabetes: KCNJ11 (n=4), 
INS (n=1), homozygous GCK (n=1).
Primary and secondary outcome measures Interviews 
audio recorded, transcribed and subjected to thematic 
content analysis.
Results 3 key themes emerged:
1. Babies were extremely ill at hospital admission, with 
extended stays in intensive care required.
2. Identification of diabetes was not ‘standardised’ and 
perceived a ‘chance’ finding.
3. Adding glucose to NBS was universally considered 
extremely positive.
Conclusions Diagnosis of neonatal diabetes is 
frequently delayed, resulting in critically ill presentation 
with prolonged intensive care support, additional 
healthcare costs and familial distress. Potential to 
detect hyperglycaemia earlier was universally endorsed 
by parents with no negative consequences identified. 
Although further study including a larger number of 
individuals is needed to confirm our findings this study 
provides the first evidence of acceptability of glucose 
testing fulfilling Wilson- Jungner criteria for implementation 
within the NBS programme.
INTRODUCTION
Neonatal diabetes mellitus (NDM) 
presenting less than 6 months of age is the 
result of severe insulin deficiency, leading 
to hyperglycaemia and has a high burden of 
morbidity and mortality. NDM has an inci-
dence of approximately 1:100 000 but reports 
range from 1 in 25 000 to 1:500 000 live 
births.1–4 There are 23 known genetic causes 
which account for >80% of cases of diabetes 
diagnosed less than 6 months of age. Most 
patients with NDM present with severe hyper-
glycaemia and diabetic ketoacidosis, asso-
ciated with prolonged hospital admission. 
Adverse outcomes include lifelong neurolog-
ical damage or death with children suffering 
quadriplegia and brain damage, as a result of 
diabetic ketoacidosis with cerebral oedema 
and coning, requiring lifelong institutional 
support.5–7 This morbidity and mortality is 
likely to be a marked underestimate as brain 
damage and death from ketoacidosis is often 
unrecognised or unrecorded. The prognosis 
is linked to the severity of the hyperglycaemia 
and ketoacidosis and crucially, the speed with 
which the disease is recognised and treat-
ment implemented. The median duration 
of diabetes at the time of genetic testing for 
monogenic causes of NDM decreased from 
more than 4 years before 2005 to less than 3 
Strengths and limitations of this study
 ► This study gained in- depth parental insight into the 
identification of neonatal diabetes and acceptability 
of newborn glucose screening.
 ► Families were from a variety of ethnic backgrounds 
and affected by five different genetic causes of 
neonatal diabetes, with varied treatments and 
prognosis.
 ► Patient and public involvement was central and find-
ings were shared with participants to ensure trust-
worthiness and credibility of data and analysis.
 ► Limitations were the small number of families inter-
viewed and therefore findings may not represent the 
views of all families with neonatal diabetes.
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months after 2012.8 This was due to the introduction of 
a very simple patient selection and testing strategy; rapid, 
high- throughput robotic Sanger sequencing analysis of 
common causes of NDM genes by the Exeter laboratory 
offered free of charge for any patient in the world with 
diabetes diagnosed under 6 months. Widespread educa-
tion and increased recognition of neonatal diabetes as a 
rare type of diabetes in addition to easily accessible free 
genetic testing contributed to the significant reduction in 
time from diabetes diagnosis to a confirmed molecular 
genetic diagnosis.
A correct genetic diagnosis of neonatal diabetes is 
important as it determines the most effective form of 
treatment. For the most common subtypes of neonatal 
diabetes due to KCNJ11 or ABCC8 mutations most indi-
viduals (>90%) can be transferred from insulin injec-
tions to sulfonylurea tablets with marked improvement in 
glycaemic control, with reductions in hypoglycaemia and 
blood glucose monitoring.9–12 Twenty per cent of muta-
tions in these genes cause neurological impairment and 
improvements in motor and cognitive function have been 
reported, with the greatest benefits seen with earlier sulfo-
nylurea treatment, leading to improved glucose control, 
neurological function and quality of life for the patient 
and their families.7 13–15
In the UK, all neonates are screened at day 5 of life as 
part of standard routine postnatal care. Sample collection 
involves a heel prick blood sample collected on specialist 
bloodspot paper cards. These are analysed by one of a 
network of National Health Service (NHS) Neonatal 
Screening Laboratories for nine rare but serious meta-
bolic diseases. This NHS routine screening service offers 
the potential for early detection of hyperglycaemia, as 
insulin deficiency from birth results in hyperglycaemia 
that can be detected in the first few days of life,16 thereby 
facilitating earlier treatment and genetic diagnosis of 
NDM.
For a specific test to be considered viable for a screening 
programme, a number of criteria have been suggested.17 
The most widely used are those proposed by Wilson- 
Jungner, which are designed to appraise the validity of a 
screening programme and have been adapted for appli-
cation to screening in the UK.18 The original criteria are:
A. The condition being screened for should be an im-
portant health problem.
B. The natural history of the condition should be well 
understood.
C. There should be a detectable early stage.
D. Treatment at an early stage should be of more benefit 
than at a later stage.
E. A suitable test should be devised for the early stage.
F. The test should be acceptable.
G. Intervals for repeating the test should be determined.
H. Adequate health service provision should be made for 
the extra clinical workload resulting from screening.
I. The risks, both physical and psychological, should be 
less than the benefits.
J. The costs should be balanced against the benefits.
Screening for NDM fulfils most criteria, with compel-
ling evidence that early identification of NDM would 
avoid many of the severe complications and mortality asso-
ciated with early unrecognised presentation of diabetes.
However, the test should also be considered 
‘acceptable’.18
Our study aimed to gain understanding of parental 
experience of the presentation and recognition of 
neonatal diabetes and their views on the acceptability of 
adding glucose testing to the national newborn bloodspot 
screening (NBS) programme.
METHODS
Recruitment
Participants were recruited from the NEWBIE 1 study, 
which comprised families that had genetic testing for 
neonatal diabetes at the Royal Devon and Exeter NHS 
Foundation Trust Clinical Laboratories from 2013 to 
2020. NEWBIE aimed to establish the diagnostic accuracy 
of newborn screening for neonatal diabetes by assessing 
glucose at day 5 of life and the clinicians of 139 chil-
dren across the UK were contacted to ask permission 
to approach these families. Agreement was provided by 
48 parents who were contacted sequentially, and verbal 
consent was taken by telephone (by KL) and consent 
forms were posted to potential participants, with 25 
subsequently returning written consent. Twenty of 25 had 
a confirmed genetic diagnosis and therefore comprised 
the potential cohort for this qualitative study.
As the families had young children and were located 
across the UK, telephone interviews were considered both 
convenient and acceptable to parents and were arranged 
for a time and date to suit themient. Ten interviews were 
conducted as data saturation was achieved at this point 
and so no further families were contacted at this stage for 
this qualitative study.
A qualitative approach, from a social constructivist 
stance, was used to gain in- depth insight into the presen-
tation and recognition of neonatal diabetes. A social 
constructivist perspective allows the experience of illness 
to be viewed from multiple perspectives as social and 
cultural constructs, with individuals’ experiences of illness 
being inextricably linked with their experience of life. 
Parent’s stories or narratives therefore provide a means of 
contextualising illness experience in a holistic biograph-
ical context. The focus of the interviews was on gaining an 
understanding of the meaning these events surrounding 
their child’s diagnosis had for the families being studied, 
and their views on the acceptability of adding glucose to 
the NBS programme.
Patient and public involvement
Patient and public involvement has been integral 
throughout the project. The study was initially discussed 
with 12 members (three with diabetes) of the National 
Institute for Health Research Exeter Clinical Research 
Facility user group and all agreed the project was feasible 
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and would provide no inconvenience. Three parents 
of children affected by neonatal diabetes were also 
contacted and unanimously supported the proposal and 
two were actively involved in the creating and reviewing 
patient information. They will also assist us in producing 
summaries of the project for dissemination to ensure 
these are clear to non- healthcare professionals and can 
have maximum impact. The findings of the study have 
also been shared with the participants as described in the 
Discussion section.
In- depth telephone interviews were conducted with 10 
parents (eight mothers and two fathers) of 14 children 
with neonatal diabetes, currently aged 1–14 years, median 
2 years. Eight of the children had transient neonatal 
diabetes: KCNJ11 (n=5), ABCC8 (n=1), 6q24 (n=2) all of 
whom were currently in remission and six had permanent 
neonatal diabetes: KCNJ11 (n=4), INS (n=1), homozygous 
GCK (n=1). Families were from a variety of ethnic groups: 
Western European (n=7), Arabic (n=1), Pakistani (n=1), 
Chinese (n=1) (table 1).
Data collection and analysis
Telephone interviews were conducted with all partici-
pants by an experienced qualitative researcher (MS), 
who introduced herself and her role within this study. She 
had previously been in contact with four of the parents 
in her capacity as senior nurse within the monogenic 
diabetes team when providing clinical advice regarding 
the management of the neonatal diabetes following a 
genetic diagnosis. Duration of the interviews was deter-
mined by the interviewee’s responses, but typically lasted 
45–60 min. Parents were previously asked to identify and 
remain in a private, quiet location for the duration of 
the interview. The interviews were semistructured with 
open questions, using a qualitative interview guide which 
focused on six domains:
1. Experiences of pregnancy/postdelivery period.
2. Recognition of diabetes.
3. Experience of genetic diagnosis.
4. Response to diagnosis and experiences since.
5. Awareness of NBS tests.
6. Views of adding glucose to the NBS and anything else 
they felt was important to allow issues that were signifi-
cant to the families to emerge.
The questions asked and prompts given around these 
domains were deliberately broad and open ended to 
allow the participants to describe the issues they consid-
ered most important, for example, ‘I’m interested to hear 
about your response to the diagnosis of neonatal diabetes and 
your experiences since….’ (see online supplemental data). 
The approach taken was flexible and iterative.
The interviews were audio recorded to ensure accu-
rate data collection and the interviewer also made notes. 
Interviews were subsequently transcribed verbatim, 
although names and identifying features were abbrevi-
ated to preserve anonymity. All participants were assigned 
a unique study ID. A thematic content analysis was under-
taken using an inductive process, this was conducted 
manually due to the small number of interviews 
conducted. Transcripts were read and re- read to enable 
the researchers to become immersed in the data. High-
lighting and colour coding of sections of text was used to 
identify potential issues and areas of interest. Notes were 
made on the transcripts to indicate the possible topic 
areas and these were compared across the different tran-
scripts to generate a list of common themes which were 
considered and refined into themes of key importance. 
Interviews were concluded after 10 interviews as data satu-
ration was achieved with no new themes emerging from 
the data. The transcripts were independently analysed 
by MS and BAK. The initial data analysis was revisited to 
refine the themes and develop subthemes with participant 
quotes identified which supported the themes. Themes 
were discussed with the research team and discrepancies 
resolved by consensus. Recurring patterns were identified 
Table 1 Characteristics of the families taking part
Participant Gene affected
PNDM/
TNDM* Ethnic group
Parent affected (confirmed by 
genetic analysis)
Currently in 
remission
1 KCNJ11 PNDM Western European No N/A
2 6q24 TNDM Western European No Yes
3 KCNJ11 TNDM Pakistani Parents heterozygous (but unaffected, 
first cousins)
Yes
4 ABCC8 TNDM Western European Mother Yes
5 GCK PNDM Arabic Parents heterozygous N/A
6 6q24 TNDM Western European No Yes
7 KCNJ11 PNDM Western European Mother N/A
8 INS PNDM Western European Mother N/A
9 KCNJ11 PNDM Chinese No N/A
10 KCNJ11 TNDM Western European Mother Yes
N/A, not applicable; PNDM, Permanent Neonatal Diabetes Mellitus; TNDM, Transient Neonatal Diabetes Mellitus.
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and relationships between the themes within and across 
transcripts were recorded. Anonymised interview tran-
scripts were stored on a password- protected computer 
within a secure (swipe card access only) research environ-
ment. The results reported in this paper focus specifically 
on the issues relating to the period prior to/during the 
diabetes diagnosis and subsequent genetic test and the 
parents’ views of NBS for glucose, other issues will be 
described as appropriate in a separate manuscript.
RESULTS
Three key themes and eight subthemes emerged:
Theme 1: babies were extremely ill when admitted to hospital
Subtheme A: parent’s concerns not being taken seriously resulted 
in delays in admission
Although symptoms of hyperglycaemia had been reported 
by parents prior to admission, these had been dismissed 
by other healthcare professionals and led to delays in 
diagnosis.
They had no suspicion at all that something can be 
wrong….even GP, doctors look at her ‘Oh yeah she’s 
so good, she’s fine’ … One day before (hospital ad-
mission) I said ‘She’s drinking a lot of milk …and 
she’s sick a lot now’ and (they said) ‘Oh it can hap-
pen it’s reflux’ (but) …she was drinking and drinking 
and drinking. (Participant 1)
Polydipsia is a recognised sign of hyperglycaemia in 
children and adults diagnosed with diabetes but that was 
not recognised in this case.
Other causes of symptoms were assumed and delays in 
admission resulted.
She’d not grown since she was 6 weeks old and she 
kept throwing up her bottles and always demanding 
more, she was always grumpy ….so we took her to the 
doctors but there was a sickness bug going round and 
they said ‘Bring her back on Monday.’ (Participant 4)
Vomiting is also known to be a feature of diabetic 
ketoacidosis but again was dismissed as having an alterna-
tive cause in both these cases.
Subtheme B: delays in admission resulted in long stays in intensive 
care required
Many of the babies were considered to be extremely ill 
when they were finally admitted to hospital and families 
recognised healthcare professionals’ concerns and babies 
were frequently taken straight to the neonatal intensive 
care units (ICU).
They were very worried, she was taken direct to ICU… 
it was a nightmare for me. (Participant 5)
Both families and healthcare professionals’ concern 
about the well- being of the baby was clearly evident. 
The uncertainty of the situation added to the families’ 
concerns.
Consequently, long stays of several weeks in intensive 
care were common and were likely to have resulted from 
delays in diagnosis and degree of hyperglycaemia on 
admission.
He was in hospital for 5 weeks altogether. (Participant 
6)
He was in 'neonatal' (ICU) for about 3 weeks. (Partic-
ipant 7)
Subtheme C: the severity of the babies’ condition on admission 
increased parental anxiety
There was clear concern regarding the baby’s chances of 
survival and this impacted emotionally on the families.
Stressed, depressed, don’t know what was going to 
happen to him, all a worry… it was frightening and 
scary and horrible. (Participant 6)
Delays in recognising the deteriorating health of the 
neonates and the significance of the symptoms resulted 
in deferral in admission, increased distress for the parents 
and prolonged hospital stays.
Theme 2: identification of diabetes was not ‘standardised’ and 
often perceived to be a ‘chance’ finding
Subtheme D: testing for glucose was often attributed to a single 
healthcare professional
A number of families considered testing of blood glucose 
was down to ‘luck’ or the attention of an individual health-
care professional as opposed to a routinely performed 
test.
One of the nurses, she was not asked to do so but, she 
did a urine sample and they found her sugars were 
abnormal and that is what made her go into the hos-
pital again so it was lucky for H to find it so early. 
(Participant 5)
Participants considered testing for glucose to be 
random, rather than a systematic investigation prior to 
ICU admission.
Where an individual healthcare professional was 
regarded as being the ‘single person’ who had identified 
the problem, questions were raised about what might 
have transpired if that healthcare professional was not 
involved.
It was just this one good doctor who came …and he 
was marvellous and luckily he come or I don’t know 
what would have happened …I mean would B have 
been in a worse state? …maybe he’d have ‘gone’ for 
ever. (Participant 6)
Parents were clearly aware their babies could have died 
if the diagnosis had been further postponed.
Subtheme E: testing for glucose was advised by the families 
themselves
One family, where the baby’s mother was known to have 
diabetes herself, had insisted their baby’s blood glucose 
tested, despite being advised to the contrary.
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She had an abscess above her bottom …and she was 
admitted … (my) Dad said ‘Mum’s diabetic, can you 
test her (the baby’s) blood sugars please?’ and they 
tried to fob us off they were ‘No, no, no, it won’t be 
anything like that’ but he was adamant …and that’s 
when they did and they (the blood sugars) were 18 … 
she was 2 weeks (of age)… it could have completely 
got missed. (Participant 8)
This reinforces the importance of healthcare profes-
sionals recognising and responding to families’ concerns.
Subtheme F: glucose values on testing were substantially raised
Extremely high levels of glucose on admission were 
common, suggesting the diagnosis of diabetes had clearly 
been delayed.
It was 30s, 36 nearly touching 40 (mmol/L) some-
times. (Participant 6)
The blood sugar was extremely high, around 40–50 
(mmol/L). (Participant 9)
Subtheme G: healthcare professionals did not anticipate diabetes 
in neonates
Healthcare professionals were not perceived to expect 
diabetes to be present at such an early age and parents 
highlighted the need for education.
They obviously didn’t have a clue about this different 
type of diabetes …they kept saying his blood sugars 
were high and they didn’t really expect anything like 
this …they weren’t aware … I do really think they 
need to know more. (Participant 7)
Healthcare professional’s lack of familiarity with 
neonatal diabetes added to the anxieties felt by the 
families.
The most difficult part for me was the beginning, 
because literally nobody knew what was going on, it 
wasn’t common, nobody knew what to do and it really 
scared us. (Participant 2)
The period prior to diagnosis and the eventual recog-
nition of a rare condition which many healthcare profes-
sionals would not be familiar with increased parental 
anxiety.
Subtheme H: despite perceiving glucose testing to be a chance 
finding parents were positive about the care their child received
Despite a lack of experience with neonatal diabetes, 
parents praised the care given by the healthcare profes-
sionals and recognised this was also a difficult circum-
stance for the teams involved.
Even though all the medical staff were absolutely 
amazing I can’t fault them …this was a very unknown 
situation for them… I could see nobody knew what to 
do really. (Participant 2)
Due to the rarity of neonatal diabetes it was unsurprising 
that many healthcare professionals were unfamiliar with 
this condition, however parents were hugely appreciative 
of the care their child received and this influenced one 
family’s view of the NHS.
I have been very, very grateful for everything that the 
diabetes specialist has done for our baby, it actually 
changed the way I think about the UK health system. 
(Participant 9)
Recognition of diabetes and testing of blood glucose 
was considered by parents to be predominantly a conse-
quence of the location of their baby, for example, in an 
intensive care setting or down to individual healthcare 
professionals, as opposed to a routine test undertaken in 
unwell neonates. Despite healthcare professionals’ unfa-
miliarity with neonatal diabetes the families were very 
grateful for the care their children received.
Theme 3: adding glucose to the NBS test was universally 
considered extremely positive
Every single parent interviewed was positive about 
the possibility of adding a glucose test onto the NBS 
programme.
I think it’s an absolutely fantastic idea I really, real-
ly do it’s brilliant … and I think if it wasn’t for me 
carrying the gene …they wouldn’t probably have 
got tested, so I think it’s an absolutely fantastic idea. 
(Participant 10)
Parents could not see any disadvantages to NBS as this 
would ensure blood glucose was measured close after 
birth and would prevent missed or delayed diagnosis.
They recognised this could avoid symptoms of hyper-
glycaemia being missed.
I think it’s a good idea, that would have been ideal 
because we went through weeks of … the symptoms 
of diabetes but not picking up on it. (Participant 4)
And recognised that testing at day 5 of life could prevent 
deterioration in the condition of babies with diabetes.
That would be a great idea, I mean before it develops 
even further… discovering this at a very early stage is 
going to be extremely helpful. (Participant 9)
Potential detection at an early stage was considered 
very valuable. Parents considered this approach would 
avoid potential problems from a delayed diagnosis.
She was lucky to be diagnosed at 10 days… I wonder 
how she survived. In the future … it would be much 
better if they were diagnosed earlier and treated ear-
lier, rather than leaving for later days and leading to 
damage for the child. (Participant 5)
They highlighted the possibility of preventing babies 
becoming seriously ill with all the fear that caused.
My baby went into coma and nearly died …so if 
they find it at day 5 …we could have avoided that. 
(Participant 1)
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Parents recognised that NBS for glucose could prevent 
babies from becoming seriously unwell and dying.
Parents were unanimous in the view that adding glucose 
to the NBS programme was a positive step which would 
reduce delayed diagnosis and deterioration in the health 
of babies with diabetes and prevent other families from 
going through the trauma they had as a consequence of 
a delayed diagnosis.
DISCUSSION
Our study provides the first evidence of parental support 
for the addition of glucose to the newborn screening 
programme and in- depth insights into the experiences 
around diabetes diagnosis during the neonatal period 
in five different genetic subtypes. The key themes identi-
fied in this study highlight the risk of a delayed diagnosis 
with hyperglycaemic symptoms often missed and diabetes 
diagnosis often considered by families to be a chance 
finding. This led to babies being extremely ill when the 
diagnosis was finally made, resulting in long hospital stays 
and high levels of distress among the families. These 
delays influenced the families’ perceptions of newborn 
glucose screening as important to prevent other families 
going through the same situation with the potential for a 
much earlier diagnosis.
Recognition and diagnosis of neonatal diabetes is 
frequently delayed with babies presenting with extreme 
hyperglycaemia, requiring extended intensive care 
support. This leads to high NHS care costs and parental 
distress. Parents considered the addition of a glucose 
measurement to NBS would reduce delays in the diag-
nosis of neonatal diabetes and prevent the extent of the 
suffering they experienced with the deteriorating health 
of their baby. No parents indicated any concerns or 
suggested any potential negative consequences of NBS 
screening for glucose within the interviews.
We have previously shown that glucose levels at day 5 of 
life in those with neonatal diabetes are already raised and 
markedly higher than the normal range,16 therefore the 
introduction of glucose as part of the newborn screening 
programme could prevent delays in recognition and 
ensure prompt treatment of neonatal diabetes.
Previous studies have explored attitudes to expanding 
newborn screening in other conditions but many have 
focused on the views of clinicians19 or parents with 
‘healthy’ children20 with far less attention paid to the 
views of families living with the conditions.21 We consid-
ered it of paramount importance to gain understanding 
of those actually experiencing the impact of neonatal 
diabetes to inform NBS for glucose as it is those who 
have lived through the experience who are best placed to 
appreciate the issues involved,
Parental views are recognised to be influenced by 
contextual factors such as personal experience.21 In fami-
lies with haemophilia the vast majority (77%) supported 
newborn screening predominantly because they consid-
ered it a means to facilitate early support and treatment, 
inform decisions about future pregnancies and prevent 
the ‘diagnostic odyssey’ and difficulties associated with a 
later diagnosis.22 Concerns about the detrimental impact, 
in terms of bonding and parental stress, that an unsought 
and serious diagnosis can have on early parent‐child rela-
tionships have been highlighted in cystic fibrosis23 24 and 
spinal muscular atrophy (SMA).25 Despite the majority 
(70%) of families and individuals living with SMA being 
in favour of newborn genetic screening due to delays 
in diagnosis, those not in favour (whose babies had an 
extremely curtailed lifespan or a longer period of time 
before the onset of symptoms) were concerned that 
newborn genetic screening would prevent families from 
enjoying carefree time with their baby before symptoms 
emerged.25
Strengths and limitations
A key strength of this study is that participants were from 
a variety of backgrounds and represented five different 
genetic causes of neonatal diabetes, with varied treat-
ments and prognosis. Parents were all able to provide 
‘insider information’ on their personal experiences of a 
delayed diagnosis of neonatal diabetes in their families. 
Copies of the draft paper were sent to the participants to 
ensure the trustworthiness and credibility of the data and 
analysis, with an invitation to provide any feedback to the 
research team. Only four of the participants responded 
to the draft paper and they indicated they were satis-
fied with the data and information included and none 
requested any edits. The number of families interviewed 
was small and therefore our findings may not represent 
the views of all families with neonatal diabetes, although 
data saturation was reached and clear themes identified. 
However, further study including more individuals would 
be required to support our findings.
CONCLUSION
Our study contributes to an emerging literature that 
considers the acceptability of newborn screening prac-
tices from the vantage point of parents with experience 
of a child with the condition. Although further study 
including a larger number of individuals is needed to 
confirm our findings this study provides new evidence 
that adding glucose to the NBS programme is not only 
acceptable to families but endorsed by them, providing 
the first confirmation of acceptability of testing, fulfilling 
one of the Wilson- Jungner criteria for adding glucose as 
part of the NBS programme.
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